Ailin Barseghian El-Farra, MD
Interventional Cardiology · Orange, CANPI 1982836466
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Amgen at 43.3% of the total.
Across 150 payments — averaging $257.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$17K
- Abbott$15K
- Novartis$3K
- Edwards Lifesciences$1K
- Abiomed$618
- Medtronic$412
- plus $2K from 13 others
Across 39 payments — averaging $16,710 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$581K
- Amgen$71K
What the payments were for
- Consulting fees$7,07518%
- Speaking & faculty fees$20,78554%
- Travel & lodging$2,9488%
- Food & beverage$7,80420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $16,710 |
| Abbott | 54 | $15,119 |
| Novartis | 9 | $2,665 |
| Edwards Lifesciences | 18 | $1,164 |
| Abiomed | 10 | $618 |
| Medtronic(2 entities) | 5 | $412 |
| Novo Nordisk | 3 | $346 |
| Shockwave Medical, Inc | 2 | $315 |
| Regeneron Healthcare Solutions, Inc. | 2 | $234 |
| AstraZeneca | 3 | $212 |
| Kowa Pharmaceuticals America, Inc. | 1 | $188 |
| Cardiovascular Systems Inc. | 4 | $161 |
| Bayer | 2 | $138 |
| Kestra Medical Technology Services, Inc. | 6 | $129 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $57 |
| Acist Medical Systems, Inc. | 2 | $47 |
| Regeneron | 1 | $42 |
| Pfizer | 1 | $30 |
| Philips North America LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$15,533
- COROFLOW$8,294
- XIENCE SIERRA$3,625
- LEQVIO$2,348
- Mitra Clip system$1,008
- SAPIEN 3 Ultra RESILIA$664
- MitraClip$329
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$315
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$289
- OPTIS$204
- Livalo$188
- CoreValve Evolut$180
- Claria MRI$140
- Wegovy$133
- CARDIOMEMS$132
- Ozempic$129
- Impella$128
- Kerendia$120
- PRALUENT$115
How this compares
$38,611 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 50 | $82,054 |
| Repatha SureclickEvolocumab | 106 | $78,967 |
| XareltoRivaroxaban | 30 | $36,181 |
| Praluent PenAlirocumab | 37 | $30,722 |
| BrilintaTicagrelor | 23 | $28,159 |
| JardianceEmpagliflozin | 23 | $17,943 |
| VascepaIcosapent Ethyl | 26 | $13,170 |
| Repatha PushtronexEvolocumab | 15 | $8,870 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $5,457 |
| Icosapent Ethyl | 29 | $5,142 |
| Rosuvastatin Calcium | 290 | $3,976 |
| Repatha SyringeEvolocumab | 12 | $3,478 |
| Ranolazine ErRanolazine | 47 | $3,364 |
| Ezetimibe | 110 | $3,234 |
| Metoprolol Succinate | 148 | $2,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $30 | $82,05450 claims |
| AstraZenecaBrilinta | $212 | $28,15923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Orange
- Brian KolskiOrange$534K
- Jeffrey TylerOrange$411K
- Arnold SetoOrange$214K
- Antonio Halais FrangiehOrange$208K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.